BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
BusinessSummit Announces Key Appointments to Strengthen Research and Development TeamBy Nasdaq OMXMay 23, 2017, 11:07 AM UTC
BusinessPhase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile InfectionBy Nasdaq OMXApr 28, 2017, 10:30 PM UTC
BusinessSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational ProgressBy Nasdaq OMXMar 29, 2017, 11:02 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational ProgressBy Nasdaq OMXMar 29, 2017, 11:02 AM UTC
BusinessSummit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare ConferenceBy Nasdaq OMXMar 15, 2017, 11:00 AM UTC
BusinessSummit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory MeetingsBy Nasdaq OMXFeb 1, 2017, 12:01 PM UTC
